[Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer]

Area of Science:

• Oncology
• Immunotherapy
• Head and Neck Cancer Treatment

Background:

• Malignant tumors pose a significant global health challenge.
• Traditional cancer treatments like chemotherapy have limitations in efficacy and side effect profiles.
• Anti-programmed cell death protein 1 (PD-1) monoclonal antibodies represent a significant advancement in cancer therapy.

Purpose of the Study:

• To review the clinical application and impact of anti-PD-1 monoclonal antibodies in treating head and neck cancer.
• To highlight the shift towards immunotherapy as a first-line treatment for recurrent/metastatic head and neck cancer.
• To discuss the expanding indications and biomarker exploration for PD-1 inhibitors.

Main Methods:

• Review of clinical studies and data on anti-PD-1 monoclonal antibody treatment for head and neck cancer.
• Analysis of treatment outcomes, including efficacy and adverse event incidence.
• Exploration of biomarker validation and expansion of therapeutic indications.

Main Results:

• Anti-PD-1 monoclonal antibodies demonstrate superior efficacy compared to traditional strategies in advanced head and neck cancer.
• Immunotherapy with PD-1 inhibitors shows a significantly lower incidence of adverse events than chemotherapy.
• In China, anti-PD-1 monoclonal antibodies have become a first-line treatment for recurrent/metastatic head and neck cancer.

Conclusions:

• Anti-PD-1 monoclonal antibodies are transforming head and neck cancer treatment paradigms.
• The individualized and precise application of PD-1 inhibitors holds promise for improving outcomes in advanced malignancies.
• Continued research and clinical trials are expanding the role and refining the use of PD-1 targeted immunotherapies.